Antibody-mediated coengagement of fcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus

Journal of Immunology

Volumn 186, Issue 7, 2011, Pages 4223-4233

  Horton, Holly M ^a   Chu, Seung Y ^a   Ortiz, Elizabeth C ^b,c   Pong, Erik ^a   Cemerski, Saso ^a   Leung, Irene W L ^a   Jacob, Noam ^c   Zalevsky, Jonathan ^a   Desjarlais, John R ^a   Stohl, William ^b,c   Szymkowski, David E ^a  

^a Xencor Inc   (United States)

^b LAC USC MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; B LYMPHOCYTE RECEPTOR; B7 ANTIGEN; CD19 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; FC RECEPTOR IIB; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG; XMAB 5871;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CALCIUM MOBILIZATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIGENS, CD19; B-LYMPHOCYTE SUBSETS; BINDING SITES, ANTIBODY; CELL COMMUNICATION; DISEASE MODELS, ANIMAL; FEMALE; GENE AMPLIFICATION; HEK293 CELLS; HUMANS; IMMUNITY, HUMORAL; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MICE; MICE, SCID; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, B-CELL; RECEPTORS, IGG;

EID: 79955019213     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003412     Document Type: Article

References (66)

1. Heyman, B. 2003. Feedback regulation by IgG antibodies. Immunol. Lett. 88: 157-161. (Pubitemid 36859980)
2. Crowley, J. E., J. E. Stadanlick, J. C. Cambier, and M. P. Cancro. 2009. FcgRIIB signals inhibit BLyS signaling and BCR-mediated BLyS receptor up-regulation. Blood 113: 1464-1473.
3. Leibson, P. J. 2004. The regulation of lymphocyte activation by inhibitory receptors. Curr. Opin. Immunol. 16: 328-336. (Pubitemid 38607380)
4. Tarasenko, T., J. A. Dean, and S. Bolland. 2007. FcgRIIB as a modulator of autoimmune disease susceptibility. Autoimmunity 40: 409-417. (Pubitemid 47343352)
5. Nimmerjahn, F., and J. V. Ravetch. 2008. Fcg receptors as regulators of immune responses. Nat. Rev. Immunol. 8: 34-47.
6. Brownlie, R. J., K. E. Lawlor, H. A. Niederer, A. J. Cutler, Z. Xiang, M. R. Clatworthy, R. A. Floto, D. R. Greaves, P. A. Lyons, and K. G. Smith. 2008. Distinct cell-specific control of autoimmunity and infection by FcgRIIb. J. Exp. Med. 205: 883-895. (Pubitemid 351549885)
7. McGaha, T. L., B. Sorrentino, and J. V. Ravetch. 2005. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307: 590-593. (Pubitemid 40165683)
8. Dharajiya, N., S. V. Vaidya, H. Murai, V. Cardenas, A. Kurosky, I. Boldogh, and S. A. Sur. 2010. FcgRIIb inhibits allergic lung inflammation in a murine model of allergic asthma. PLoS ONE 5: E9337.
9. Floto, R. A., M. R. Clatworthy, K. R. Heilbronn, D. R. Rosner, P. A. MacAry, A. Rankin, P. J. Lehner, W. H. Ouwehand, J. M. Allen, N. A. Watkins, and K. G. Smith. 2005. Loss of function of a lupus-associated FcgRIIb polymorphism through exclusion from lipid rafts. Nat. Med. 11: 1056-1058. (Pubitemid 41486826)
10. Tsuchiya, N., Z. Honda, and K. Tokunaga. 2006. Role of B cell inhibitory receptor polymorphisms in systemic lupus erythematosus: A negative times a negative makes a positive. J. Hum. Genet. 51: 741-750. (Pubitemid 44386816)
11. Tackenberg, B., I. Jelcic, A. Baerenwaldt, W. H. Oertel, N. Sommer, F. Nimmerjahn, and J. D. Lünemann. 2009. Impaired inhibitory Fcg receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc. Natl. Acad. Sci. USA 106: 4788-4792.
12. Mackay, M., A. Stanevsky, T. Wang, C. Aranow, M. Li, S. Koenig, J. V. Ravetch, and B. Diamond. 2006. Selective dysregulation of the FcgIIB receptor on memory B cells in SLE. J. Exp. Med. 203: 2157-2164. (Pubitemid 44352236)
13. Su, K., H. Yang, X. Li, X. Li, A. W. Gibson, J. M. Cafardi, T. Zhou, J. C. Edberg, and R. P. Kimberly. 2007. Expression profile of FcgRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J. Immunol. 178: 3272-3280. (Pubitemid 46333211)
14. Enyedy, E. J., J. P. Mitchell, M. P. Nambiar, and G. C. Tsokos. 2001. Defective FcgRIIb1 signaling contributes to enhanced calcium response in B cells from patients with systemic lupus erythematosus. Clin. Immunol. 101: 130-135.
15. Veri, M. C., S. Burke, L. Huang, H. Li, S. Gorlatov, N. Tuaillon, G. J. Rainey, V. Ciccarone, T. Zhang, K. Shah, et al. 2010. Therapeutic control of B cell activation via recruitment of Fcg receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum. 62: 1933-1943.
16. Meeker, T. C., R. A. Miller, M. P. Link, J. Bindl, R. Warnke, and R. Levy. 1984. A unique human B lymphocyte antigen defined by a monoclonal antibody. Hybridoma 3: 305-320. (Pubitemid 15126236)
17. Chu, S. Y., I. Vostiar, S. Karki, G. L. Moore, G. A. Lazar, E. Pong, P. F. Joyce, D. E. Szymkowski, and J. R. Desjarlais. 2008. Inhibition of B cell receptormediated activation of primary human B cells by coengagement of CD19 and FcgRIIb with Fc-engineered antibodies. Mol. Immunol. 45: 3926-3933.
18. Horton, H. M., M. J. Bernett, E. Pong, M. Peipp, S. Karki, S. Y. Chu, J. O. Richards, I. Vostiar, P. F. Joyce, R. Repp, et al. 2008. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 68: 8049-8057.
19. Zalevsky, J., I. W. Leung, S. Karki, S. Y. Chu, E. A. Zhukovsky, J. R. Desjarlais, D. F. Carmichael, and C. E. Lawrence. 2009. The impact of Fc engineering on an anti-CD19 antibody: Increased Fcg receptor affinity enhances B-cell clearing in nonhuman primates. Blood 113: 3735-3743.
20. Maloney, D. G., B. Smith, and A. Rose. 2002. Rituximab: Mechanism of action and resistance. Semin. Oncol. 29(1 Suppl. 2)2-9. (Pubitemid 34171789)
21. Lazar, G. A., W. Dang, S. Karki, O. Vafa, J. S. Peng, L. Hyun, C. Chan, H. S. Chung, A. Eivazi, S. C. Yoder, et al. 2006. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 103: 4005-4010.
22. Veri, M. C., S. Gorlatov, H. Li, S. Burke, S. Johnson, J. Stavenhagen, K. E. Stein, E. Bonvini, and S. Koenig. 2007. Monoclonal antibodies capable of discriminating the human inhibitory Fcg-receptor IIB (CD32B) from the activating Fcgreceptor IIA (CD32A): Biochemical, biological and functional characterization. Immunology 121: 392-404. (Pubitemid 46817361)
23. Okazaki, M., Y. Luo, T. Han, M. Yoshida, and B. K. Seon. 1993. Three new monoclonal antibodies that define a unique antigen associated with prolymphocytic leukemia/non-Hodgkin's lymphoma and are effectively internalized after binding to the cell surface antigen. Blood 81: 84-94. (Pubitemid 23013681)
24. Clark, E. A., and J. A. Ledbetter. 1986. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc. Natl. Acad. Sci. USA 83: 4494-4498. (Pubitemid 16057075)
25. Krop, I., A. R. de Fougerolles, R. R. Hardy, M. Allison, M. S. Schlissel, and D. T. Fearon. 1996. Self-renewal of B-1 lymphocytes is dependent on CD19. Eur. J. Immunol. 26: 238-242. (Pubitemid 26028440)
26. Ahuja, A., J. Shupe, R. Dunn, M. Kashgarian, M. R. Kehry, and M. J. Shlomchik. 2007. Depletion of B cells in murine lupus: Efficacy and resistance. J. Immunol. 179: 3351-3361.
27. Bombardier, C., D. D. Gladman, M. B. Urowitz, D. Caron, C. H. Chang; The Committee on Prognosis Studies in SLE. 1992. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum. 35: 630-640.
28. Petri, M., M. Y. Kim, K. C. Kalunian, J. Grossman, B. H. Hahn, L. R. Sammaritano, M. Lockshin, J. T. Merrill, H. M. Belmont, A. D. Askanase, et al; OC-SELENA Trial. 2005. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med. 353: 2550-2558. (Pubitemid 41785892)
29. Duchosal, M. A., P. J. McConahey, C. A. Robinson, and F. J. Dixon. 1990. Transfer of human systemic lupus erythematosus in severe combined immunodeficient (SCID) mice. J. Exp. Med. 172: 985-988. (Pubitemid 20301248)
30. Sthoeger, Z., H. Zinger, B. Dekel, F. Arditi, Y. Reisner, and E. Mozes. 2003. Lupus manifestations in severe combined immunodeficient (SCID) mice and in human/mouse radiation chimeras. J. Clin. Immunol. 23: 91-99. (Pubitemid 36324199)
31. Schwartz, R. H. 2003. T cell anergy. Annu. Rev. Immunol. 21: 305-334. (Pubitemid 37174534)
32. Rankin, C. T., M. C. Veri, S. Gorlatov, N. Tuaillon, S. Burke, L. Huang, H. D. Inzunza, H. Li, S. Thomas, S. Johnson, et al. 2006. CD32B, the human inhibitory Fc-g receptor IIB, as a target for monoclonal antibody therapy of Bcell lymphoma. Blood 108: 2384-2391. (Pubitemid 44497523)
33. Folzenlogen, D., M. F. Hofer, D. Y. Leung, J. H. Freed, and M. K. Newell. 1997. Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients. Clin. Immunol. Immunopathol. 83: 199-204. (Pubitemid 27244306)
34. Bijl, M., G. Horst, P. C. Limburg, and C. G. Kallenberg. 2001. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 60: 523-526. (Pubitemid 32417429)
35. Niederer, H. A., M. R. Clatworthy, L. C. Willcocks, and K. G. Smith. 2010. FcgRIIB, FcgRIIIB, and systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1183: 69-88.
36. Stohl, W. 2004. Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders. Expert Opin. Ther. Targets 8: 177-189. (Pubitemid 38877670)
37. Petri, M., W. Stohl, W. Chatham, W. J. McCune, M. Chevrier, J. Ryel, V. Recta, J. Zhong, and W. Freimuth. 2008. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 58: 2453-2459.
38. Groom, J. R., C. A. Fletcher, S. N. Walters, S. T. Grey, S. V. Watt, M. J. Sweet, M. J. Smyth, C. R. Mackay, and F. Mackay. 2007. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J. Exp. Med. 204: 1959-1971. (Pubitemid 47236330)
39. Coggeshall, K. M. 2002. Regulation of signal transduction by the Fc g receptor family members and their involvement in autoimmunity. Curr. Dir. Autoimmun. 5: 1-29.
40. Ashany, D., J. Hines, A. Gharavi, J. Mouradian, and K. B. Elkon. 1992. Analysis of autoantibody production in SCID-systemic lupus erythematosus (SLE) chimeras. Clin. Exp. Immunol. 88: 84-90.
41. Stohl, W., and R. J. Looney. 2006. B cell depletion therapy in systemic rheumatic diseases: Different strokes for different folks? Clin. Immunol. 121: 1-12. (Pubitemid 44380406)
42. Merrill, J. T., C. M. Neuwelt, D. J. Wallace, J. C. Shanahan, K. M. Latinis, J. C. Oates, T. O. Utset, C. Gordon, D. A. Isenberg, H. J. Hsieh, et al. 2010. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62: 222-233.
43. Furie, R., R. J. Looney, B. Rovin, K. M. Latinis, G. Appel, J. Sanchez-Guerrero, F. C. Fervenza, R. Maciuca, P. Brunetta, D. Zhang, and J. Garg. 2009. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): Results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum. 60(Suppl. 10): 1149 (Abstr.).
44. Ramos-Casals, M., C. Díaz-Lagares, and M. A. Khamashta. 2009. Rituximab and lupus: Good in real life, bad in controlled trials. Comment on the article by Lu et al. Arthritis Rheum. 61: 1281-1282.
45. Gasnault, J., M. Kahraman, M. G. de Goër de Herve, D. Durali, J. F. Delfraissy, and Y. Taoufik. 2003. Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS 17: 1443-1449. (Pubitemid 36900544)
46. Weber, F., C. Goldmann, M. Krämer, F. J. Kaup, M. Pickhardt, P. Young, H. Petry, T. Weber, and W. Lüke. 2001. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann. Neurol. 49: 636-642. (Pubitemid 32429790)
47. Carson, K. R., A. M. Evens, E. A. Richey, T. M. Habermann, D. Focosi, J. F. Seymour, J. Laubach, S. D. Bawn, L. I. Gordon, J. N. Winter, et al. 2009. Progressive multifocal leukoencephalopathy after rituximab therapy in HIVnegative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113: 4834-4840.
48. Wallace, D. J., W. Stohl, R. A. Furie, J. R. Lisse, J. D. McKay, J. T. Merrill, M. A. Petri, E. M. Ginzler, W. W. Chatham, W. J. McCune, et al. 2009. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61: 1168-1178.
49. Navarra, S. V., R. M. Guzman, A. E. Gallacher, S. Hall, R. A. Levy, R. E. Jimenez, E. K.-M. Li, M. Thomas, H.-Y. Kim, M. Leon, et al. 2011. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. In press.
50. Looney, R. J., J. H. Anolik, D. Campbell, R. E. Felgar, F. Young, L. J. Arend, J. A. Sloand, J. Rosenblatt, and I. Sanz. 2004. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50: 2580-2589. (Pubitemid 39062719)
51. Cambridge, G., D. A. Isenberg, J. C. Edwards, M. J. Leandro, T. S. Migone, M. Teodorescu, and W. Stohl. 2008. B cell depletion therapy in systemic lupus erythematosus: Relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 67: 1011-1016. (Pubitemid 351956665)
52. Bolland, S., and J. V. Ravetch. 2000. Spontaneous autoimmune disease in FcgRIIB-deficient mice results from strain-specific epistasis. Immunity 13: 277-285.
53. Chan, P. L., and N. R. Sinclair. 1971. Regulation of the immune response. V. An analysis of the function of the Fc portion of antibody in suppression of an immune response with respect to interaction with components of the lymphoid system. Immunology 21: 967-981.
54. Samuelsson, A., T. L. Towers, and J. V. Ravetch. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 484-486. (Pubitemid 32097072)
55. Depoil, D., S. Fleire, B. L. Treanor, M. Weber, N. E. Harwood, K. L. Marchbank, V. L. Tybulewicz, and F. D. Batista. 2008. CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand. Nat. Immunol. 9: 63-72. (Pubitemid 350286205)
56. Monroe, J. G. 2006. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat. Rev. Immunol. 6: 283-294.
57. Paul, W. E. 1991. Interleukin-4: A prototypic immunoregulatory lymphokine. Blood 77: 1859-1870.
58. Schneider, P., F. MacKay, V. Steiner, K. Hofmann, J. L. Bodmer, N. Holler, C. Ambrose, P. Lawton, S. Bixler, H. Acha-Orbea, et al. 1999. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 189: 1747-1756. (Pubitemid 29272691)
59. Gross, J. A., J. Johnston, S. Mudri, R. Enselman, S. R. Dillon, K. Madden, W. Xu, J. Parrish-Novak, D. Foster, C. Lofton-Day, et al. 2000. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404: 995-999. (Pubitemid 30243593)
60. Mackay, F., S. A. Woodcock, P. Lawton, C. Ambrose, M. Baetscher, P. Schneider, J. Tschopp, and J. L. Browning. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190: 1697-1710. (Pubitemid 30002351)
61. Khare, S. D., I. Sarosi, X. Z. Xia, S. McCabe, K. Miner, I. Solovyev, N. Hawkins, M. Kelley, D. Chang, G. Van, et al. 2000. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc. Natl. Acad. Sci. USA 97: 3370-3375. (Pubitemid 30183309)
62. Aderem, A., and R. J. Ulevitch. 2000. Toll-like receptors in the induction of the innate immune response. Nature 406: 782-787.
63. Hu, C. Y., D. Rodriguez-Pinto, W. Du, A. Ahuja, O. Henegariu, F. S. Wong, M. J. Shlomchik, and L. Wen. 2007. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117: 3857-3867. (Pubitemid 350224095)
64. Matsushita, T., K. Yanaba, J. D. Bouaziz, M. Fujimoto, and T. F. Tedder. 2008. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118: 3420-3430.
65. Hawker, K., P. O'Connor, M. S. Freedman, P. A. Calabresi, J. Antel, J. Simon, S. Hauser, E. Waubant, T. Vollmer, H. Panitch, et al; OLYMPUS trial group. 2009. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 66: 460-471.
66. Wu, H., D. S. Pfarr, S. Johnson, Y. A. Brewah, R. M. Woods, N. K. Patel, W. I. White, J. F. Young, and P. A. Kiener. 2007. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368: 652-665. (Pubitemid 46527610)